RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Review, H1 2018

  • ID: 4473113
  • Drug Pipelines
  • 55 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Basilea Pharmaceutica Ltd
  • CBT Pharmaceuticals Inc
  • Novartis AG
  • Redx Pharma Plc
  • VG Life Sciences Inc
  • MORE
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Review, H1 2018

Summary:

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - RAF proto-oncogene serine/threonine-protein kinase or proto-oncogene c-RAF is an enzyme is encoded by the RAF1 gene. Once activated the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. It plays an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration.

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Colorectal Cancer, Melanoma, Breast Cancer, Liver Cancer, Metastatic Melanoma, Pancreatic Cancer, Bladder Cancer, Colon Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Low-Grade Glioma, Lung Adenocarcinoma, Lung Cancer, Metastatic Ovarian Cancer, Multiple Myeloma (Kahler Disease) and Sarcomas.

The latest report RAF Proto Oncogene SerineThreonine Protein Kinase - Pipeline Review, H1 2018, outlays comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)
  • The report reviews RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics
Reasons to Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Basilea Pharmaceutica Ltd
  • CBT Pharmaceuticals Inc
  • Novartis AG
  • Redx Pharma Plc
  • VG Life Sciences Inc
  • MORE
Introduction

Report Coverage

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Overview

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

Basilea Pharmaceutica Ltd

CBT Pharmaceuticals Inc

Chugai Pharmaceutical Co Ltd

Hanmi Pharmaceuticals Co Ltd

Millennium Pharmaceuticals Inc

Novartis AG

Redx Pharma Plc

VG Life Sciences Inc

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Drug Profiles

(MG-005 + sorafenib) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAL-3833 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBT-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCBCI-0902 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FYA-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-95573 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydroxychloroquine + sorafenib tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LXH-254 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REDX-05358 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7304 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit RAF1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CRAF and BRAF for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Pan-RAF Kinase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-580 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Dormant Products

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Discontinued Products

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Product Development Milestones

Featured News & Press Releases

May 05, 2017: Hanmi Pharmaceutical Announced IND Approval of HM95573, a Novel Oral RAF inhibitor

Jan 06, 2017: Hanmi presents pan-RAF inhibitor preclinical trial results at Europe Cancer Symposium

Jun 17, 2016: Hanmi presented the clinical trial results of targeted anti-cancer drug HM95573 at ASCO

Jun 09, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at ASCO meeting

Apr 21, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at AACR meeting

Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent

Nov 10, 2014: Hanmi To Initiate A Phase 1 Clinical Trial Of HM95573, The Next Generation Targeted Therapy For Melanoma Treatment

Sep 04, 2014: VG Life Sciences Progress Update Phase I Cancer Study

Mar 14, 2014: VG Life Sciences's Reports on Clinical Outcomes in Phase I Cancer Study

Dec 13, 2013: VG Life Sciences Update on Phase I Cancer Study

Jul 25, 2013: VG Life Sciences Reports on Scientific Advancements: Completion of Third Cohort of Phase I Clinical Trial; Grant from the American Heart Association;

Apr 04, 2013: VG Life Sciences Reports Positive Safety Results Of Hydroxychloroquine And Sorafenib Combination Therapy In Second Cohort Of Phase I Solid Tumor Study

Jan 31, 2013: VG Life Sciences Reports Positive Results From Phase I Ovarian Cancer Trial Using Sorafenib Combined With Hydroxychloroquine

Jan 14, 2013: VG Life Sciences Receives IRB Approval To Expand Phase I Cancer Trial Of Hydroxychloroquine In Combination With Sorafenib

Jul 19, 2012: Viral Genetics Begins Phase I Clinical Trial For Ovarian Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Basilea Pharmaceutica Ltd, H1 2018

Pipeline by CBT Pharmaceuticals Inc, H1 2018

Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018

Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018

Pipeline by Millennium Pharmaceuticals Inc, H1 2018

Pipeline by Novartis AG, H1 2018

Pipeline by Redx Pharma Plc, H1 2018

Pipeline by VG Life Sciences Inc, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures:

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administrations, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Basilea Pharmaceutica Ltd
  • CBT Pharmaceuticals Inc
  • Chugai Pharmaceutical Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Millennium Pharmaceuticals Inc
  • Novartis AG
  • Redx Pharma Plc
  • VG Life Sciences Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll